As we showed in 2009, MET is highly expressed, amplified, and mutated in HNSCC; moreover, we demonstrated that MET inhibition abrogated cell proliferation and migration/motility, suggesting that MET would be an effective target in HNSCC [3]. Here, MET is linked to head and neck squamous cell carcinoma.